Interaction between B.7 and CD28 costimulatory molecules is essential for the activation of effector function mediating spontaneous tumour regression

Scandinavian Journal of Immunology

Volumn 49, Issue 6, 1999, Pages 633-640

  Rao, K L ^a   Varalakshmi, C H ^a   Kumari, A L ^a   Khar, Ashok ^a  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HISTIOCYTOMA; MALE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN CELL; TARGET CELL; TUMOR CELL LINE; TUMOR REGRESSION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; CYTOTOXICITY, IMMUNOLOGIC; HISTIOCYTOMA, BENIGN FIBROUS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; NEOPLASM REGRESSION, SPONTANEOUS; RATS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032973249     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1999.00550.x     Document Type: Article

References (47)

1. 1 Hellstrom KE, Hellstrom I. Principles of tumor immunity: tumor antigens. In: Devita VT, Hellman S Jr, Rosenberg SR, eds. The Biological Therapy of Cancer. Philadelphia: J.B. Lippincott Co., 1991:35-52.
2. 2 Melief CJM. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992;58:143-75.
3. 3 Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion vs function clonal inactivation: a costimulatory pathway determines the outcome of T cell receptor occupancy. Annu Rev Immunol 1989;7:445-80.
4. 4 Liu Y, Linsley PS. Costimulation of T cell growth. Curr Opin Immunol 1992;4:265-70.
5. 5 Townsend A, Bodmer H. Antigen recognition hy class I-restricted T lymphocytes. Annu Rev Immunol 1989;7:601-24.
6. 6 Altman A, Coggeshall KM, Mustelin T. Molecular events mediating T cell activation. Adv Immunol 1990;48:227-41.
7. 7 Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349-56.
8. 8 June CH, Bluestone JA, Nadler LM, Thompson CB. The B.7 and CD28 receptor families. Immunol Today 1994;15:321-31.
9. 9 Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191-212.
10. 10 Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989;143:2714-22.
11. 11 Inaba K, Witmer-Pack M, Inaba M, Hathcock KS, Sakuta H, Azuma M, Yagita H, Okumura K, Linsley PS, Ikehara S. The tissue distribution of B7-2 costimulation in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 1994;180:1849-60.
12. 12 Tan P, Anasetti C, Hansen JA, Ledbetter JA, Linsley PS. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J. Exp. Med. 1993;177:165-73.
13. 13 Lenschow DJ, Zeng Y, Thistlewaite JR, Montag A, Brudy W, Gibson MG, Linsley PS, Bluestone JA. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4-Ig. Science 1992;257:789-92.
14. 14 Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28 mediated signalling co-stimulates murine T cells and prevents induction of anergy in T cell clones. Nature 1992;356:607-9.
15. 15 Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL. CD28 interaction with B7 costimulates primary allogeneic proliferative response and cytotoxicity mediated by small resting T lymphocytes. J Exp Med 1992;175:353-60.
16. 16 Nandi D, Gross JA, Allison JP. CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol 1994;152:3361-9.
17. 17 Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, Leiden JM, June CH. CD28 activation pathway regulates the production of multiple T-cell derived lymphokines/ cytokines. Proc Natl Acad Sci USA 1989;86:1333-7.
18. 18 Wu T-C, Huang AYC, Jaffee CM, Levetsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor regression. J. Exp. Med. 1995;182:1415-21.
19. 19 Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
20. 20 Baskar S, Ostrand RS, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibilily complex class II molecules. Proc Natl Acad Sci USA 1993;90:5687-90.
21. 21 Townsend SE, Allison JP. Tumor regression after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-70.
22. 22 Khar A. Development and characterization of a rat histiocytemacrophage tumor line. J Natl Cancer Inst 1986;76:871-8.
23. 23 Kausalya S, Hegde SP, Bright JJ, Khar A. Mechanism of antibody-dependent natural killer cell mediated AK-5 tumor cell death. Exp Cell Res 1994;212:285-90.
24. 24 Kausalya S, Pardhasaradhi BVV, Manogaran PS, Khar A. Conjugate formation between effector and target as a function of cytotoxicity in antibody-dependent killing of AK-5 tumor. Indian J Exp Biol 1995;33:161-4.
25. 25 Hegde SP, Bright JJ, Kausalya S, Khar A. AK-5 tumor induced expression of IL-12; role of IL-12 in NK-medialed AK-5 regression. Cell Immunol 1995;162:241-7.
26. 26 Kausalya S, Varalakshmi C, Khar A. Correlation of in vitro and in vivo effects of interferon-γ with the spontaneous regression of a rat histiocytoma. J Interferon Cytokine Res 1995;15:647-54.
27. 27 Khar A, Kausalya S, Kamal MA. AK-5 tumor induced modulation of host immune function, upregulation of Th1 type cytokine response mediates early tumor regression. Cytokines Mol Ther 1996;2:39-48.
28. 28 Mossmann T, Cherwinski H, Bond M, Giedlin M, Coffman R. Two types of murine helper T cell clone: definition according to profile of lymphokine activities and secreted proteins. J Immunol 1994; 136:2348-57.
29. 29 Cherwinski H, Schumacher J, Brown K, Mosmann T. Two types of mouse helper T cell clone: further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays and monoclonal antibodies. J Exp Med 1987;166:1229-44.
30. 30 D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E, Chizzonite R, Wolf SF, Trinchieri G. Production of NK cell stimulatory factor (interleukin-12) by peripheral blood mononuclcar cells. J Exp Med 1992;176:1387-98.
31. 31 Mosmann T, Schumacher JH, Fiorentino DF, Leverah J, Moore KW, Bond MW. Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6 and a new Th2-specific cytokine IL-10, cytokine synthesis inhibitory factor, by using a solid phase radio-immuno-adsorbent assay. J Immunol 1990;145:2938-45.
32. 32 Kuchroo VK, Das MP, Brown JA, Ranger AM, Zanvill SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH. B7.1 and B7.2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80:707-18.
33. 33 Chomozynski P, Sacchi N. Single step method of RNA isolation by acid guanidium thiocyanate-phenol chloroform extraction. Analyt Biochem 1987;162:156-9.
34. 34 Koch J, Kolvraa S, Bolund L. An improved method for labeling of DNA probes by nick translation. Nucleic Acids Res 1986;14:7132-5.
35. 35 Bright JJ, Hegde SP, Begum Z, Khar A. Modulation of natural killer cell function leading to spontaneous regression of a histiocytoma. Cell Immunol 1994;154:54-6
36. 36 Ijsselmuiden OE, Herbrink P, Meddens MJM, Tank B, Stolz E, Van Eijk RVW. Optimizing the solid-phase immunotilteration assay: a rapid alternative to immune assays. J Immunol Methods 1989; 119:35-43.
37. 37 Khar A. Characterization of spontaneous immunological regression in a histiocytoma: I. role of NK cells and antitumor antibodies. Int J Oncol 1993;2:393-8.
38. 38 Schwartz RH. Costimulation of T lymphocytes: the role of CD28 CTLA-4 and B7/BB:1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-72.
39. 39 Geldhof AB, Raes G, Bakkus M, Devos S, Thielemans K, Baetselier PD. Expression of B7.1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res 1995;55:2730-3.
40. 40 Giandomenica I, Protti MP, Rugarli C, Bellone M. B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines. Cancer Res 1996;56:11-15.
41. 41 Roger R, Breard J, Comisso M, Bohuon C, Pallardy M, Bertoglio J. CD28-mcdiated cytotoxicity of YT natural killer cells on B7-positive targets induces rapid necrotic death independent of granule exocytosis. Cell Immunol 1996;168:24-32.
42. 42 Sperling AI, Auger JA, Ehst BD, Rulifson IC, Thompson CB, Bluestone JA. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J Immunol 1996;157:3909-17.
43. 43 Fraser JD, Inring BA, Crabtree GR, Weiss A. Regression of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991;251:313-16.
44. 44 Coughlin CM, Wysocka M, Kurzawa HL, Lee WMF, Trinchieri G, Eck SL. B7 and IL-12 synergistically induce effective antitumor immunity. Cancer Res 1995;55:4980-7.
45. 45 Martin-Fontecha A, Cavallo F, Bellone M, Heltai S, Iezzi G, Tornaghi P, Nabavi N, Forni G, Dellabona P, Casorati G. Heterogenous effects of B7.1 and B7.2 in the induction of both protective and therapeutic antitumor immunity against different mouse tumors. Eur J Immunol 1996;26:1851-9.
46. 46 Greenfield EA, Howard E, Paradis T, Nguyen K, Benazzo F, McLean P, Höllsberg P, Davis G, Hafler DA, Sharpe AH, Freeman GJ, Kuchroo VK. B7.2 expressed by T cell does not induce CD28-mediated costimulatory activity but retains CTLA-4 binding. J Immunol 1997;158:2025-34.
47. 47 Chambers BJ, Salcedo M, Ljunggren H-S. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 1996;5:311-17.